trial
as of 2026-07-01A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
NCTId NCT01678755
at a glance
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
157 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2012-08
Primary completion
2014-03
Eligibility
ALL · 20 Years · 55 Years
Interventions & indications
Drugs
Indications
Sponsors
AbbVieLead Sponsor
Investigators
1
George Haig, PharmDStudy Director
Sites
20 total
Chino, United StatesGarden Grove, United StatesNational City, United StatesOceanside, United StatesOrange, United StatesSan Diego, United StatesTorrance, United StatesBradenton, United StatesMaitland, United StatesAtlanta, United StatesChicago, United StatesHoffman Estates, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
157
Phase
PHASE2
Primary Completion Date
2014-03
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
indication
indication
investigator
person